Page last updated: 2024-10-15
cgp 43902a
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 135430705 |
| CHEMBL ID | 311929 |
| MeSH ID | M0180067 |
Synonyms (11)
| Synonym |
|---|
| CHEMBL311929 |
| cgp 43902a |
| cgp43902a |
| cgp-43902a |
| l 2-9 |
| 1-(n-ethoxycarbonylmethylpyridoxylidenium)-2-(2'-pyridyl)hydrazine |
| l2-9 |
| pyridinium, 1-(2-ethoxy-2-oxoethyl)-3-hydroxy-5-(hydroxymethyl)-2-methyl-4-((2-pyridinylhydrazono)methyl)-, bromide |
| l-2-9 |
| 124076-31-9 |
| AKOS040751106 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID197964 | Activity against metalloenzyme Ribonucleoside diphosphate reductase was evaluated from a subcutaneously growing murine tumor (sarcoma 180) implanted in B6D2F3 male mice at 1.0 conc | 1999 | Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2 | Domain-structured N1,N2-derivatized hydrazines as inhibitors of ribonucleoside diphosphate reductase: redox-cycling considerations. |
| AID197973 | Inhibition of metalloenzyme Ribonucleoside diphosphate reductase. | 1999 | Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2 | Domain-structured N1,N2-derivatized hydrazines as inhibitors of ribonucleoside diphosphate reductase: redox-cycling considerations. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||